🇺🇸 FDA
Pipeline program

BCT197 Part A

CBCT197A2202

Phase 2 small_molecule terminated

Quick answer

BCT197 Part A for Acute Kidney Injury is a Phase 2 program (small_molecule) at Mereo BioPharma Group plc with 1 ClinicalTrials.gov record(s).

Program details

Company
Mereo BioPharma Group plc
Indication
Acute Kidney Injury
Phase
Phase 2
Modality
small_molecule
Status
terminated

Clinical trials